麗珠醫藥(01513.HK)聯合申報注射劑開展三期臨床試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

麗珠醫藥(01513.HK)聯合申報注射劑開展三期臨床試驗

阿思達克 07-03 10:10

麗珠醫藥(01513.HK)公布，控股附屬公司麗珠單抗與北京鑫康合生物醫藥科技聯合申報的重組抗人IL-17A/F人源化單克隆抗體注射液已完成二期臨床試驗，並於近日開展三期臨床試驗。該注射劑已完成二期臨床試驗期中分析，研究結果顯示整體安全性良好，常見不良事件發生率與同靶點藥物類似，且具有起效快及療效維持時間長等特點。此次擬開展的是一項多中心、隨機、雙盲、陽性對照三期臨床試驗，旨在評估對比司庫奇尤單抗(商品名為可善挺)治療中度至重度慢性斑塊狀銀屑病的有效性和安全性。

麗珠醫藥(01513.HK)

Relevant Stocks

麗珠醫藥(01513.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

麗珠醫藥(01513.HK)聯合申報注射劑開展三期臨床試驗

Services

About Us

Agreement Statement